Six-dog study highlights challenges of M. abscessus infection: full analysis

A new retrospective study in the Journal of Small Animal Practice examines six dogs with confirmed Mycobacterium abscessus infection, offering a closer look at how this rare canine infection presents and how difficult it can be to manage. Based on the abstract, the dogs showed either respiratory or cutaneous disease, diagnosis was confirmed with culture and PCR, and treatment relied on clarithromycin-based protocols. Outcomes were mixed, ranging from recovery to relapse and euthanasia, underscoring the clinical uncertainty that still surrounds rapidly growing mycobacterial infections in dogs. (ovid.com)

That matters because the veterinary literature on canine M. abscessus remains thin. Older reports on rapidly growing mycobacteria in dogs and cats describe these organisms most often in chronic, nonhealing skin lesions, with occasional pulmonary involvement. More recent veterinary references still frame the M. chelonae-abscessus group as uncommon, difficult to diagnose, and therapeutically frustrating because susceptibility patterns are variable and prolonged multidrug treatment is often needed. (pubmed.ncbi.nlm.nih.gov)

The six-dog series appears to reinforce several of those themes. The abstract indicates that presentations clustered into two patterns, respiratory and cutaneous disease, and that routine diagnostics alone were not enough for definitive diagnosis. Instead, the authors used mycobacterial culture and polymerase chain reaction to confirm M. abscessus. That’s consistent with broader veterinary guidance, which emphasizes organism identification and, when possible, susceptibility testing before committing to long treatment courses. BSAVA guidance for mycobacterial infections notes that for the M. chelonae-abscessus group, macrolides are commonly paired with another active drug, while resistance and drug-interaction issues can complicate case management. (bsavalibrary.com)

The clarithromycin-based treatment approach in the study also fits what’s been described elsewhere in companion-animal mycobacterial care. Veterinary reviews have identified clarithromycin as a preferred macrolide in dogs because dosing is practical, but they also stress that treatment is rarely simple. Courses can extend for six months or longer, and even then, remission is not guaranteed. In a recent canine Mycobacterium avium report, authors described relapse despite multidrug therapy, highlighting a challenge that likely carries over to other non-tuberculous mycobacterial infections. Human infectious disease literature on M. abscessus similarly describes the pathogen as one of the least antimicrobial-susceptible mycobacteria, which helps explain why outcomes can be inconsistent even when treatment is aggressive. (vettimes.com)

Broader context adds another layer. Non-tuberculous mycobacteria are environmental organisms, and M. abscessus has been linked in human medicine to water-associated exposure and post-traumatic or pulmonary infections. A 2025 respiratory study pointed to drinking water as a possible source of clonally related M. abscessus isolates in people, though that finding shouldn’t be directly extrapolated to dogs without species-specific evidence. Still, it supports the general view that these pathogens can be acquired from the environment rather than through classic contagious spread, which has implications for history-taking and infection-control discussions in practice. (academic.oup.com)

Why it matters: For veterinarians, this case series is less about prevalence and more about pattern recognition. Dogs with persistent draining tracts, nodular dermatitis, pyogranulomatous inflammation, or chronic respiratory disease that fails to respond to standard antibiotics may warrant earlier consideration of non-tuberculous mycobacteria, including M. abscessus. Confirmatory testing matters, both to avoid missed diagnoses and to guide antimicrobial decisions in a disease area where stewardship concerns are significant. There’s also a client-communication component: treatment can be prolonged, expensive, and uncertain, and practices may need to discuss household risk carefully when immunocompromised pet parents are involved, even though zoonotic risk varies by species and circumstance. (vettimes.com)

Expert reaction specific to this six-dog paper was limited in public sources at the time of writing, but the broader specialty conversation has been consistent. Veterinary commentators describe mycobacterial infections in companion animals as increasing diagnostic challenges that require commitment from both clinicians and pet parents, especially because relapse, adverse effects, and long treatment durations are common themes. That framing matches the study’s reported outcomes and suggests the paper will be most useful as a practical reminder to test early and counsel clearly rather than as a definitive treatment roadmap. (vettimes.com)

What to watch: The next step is the full article itself. Clinicians will want the complete case details, including lesion distribution, imaging findings, susceptibility data if available, duration of therapy, adverse events, and any common factors among the dogs that recovered versus those that relapsed or were euthanized. Those details will determine whether this report changes day-to-day diagnostic workups or mainly strengthens existing caution around chronic cutaneous and respiratory mycobacterial disease in dogs. (ovid.com)